5 min read
The Long View: Pharma Is Paying More For Less-Proven Science
A decade of deal data shows the premium has migrated to earlier-stage assets and a shrinking set of modalities. The reference points business development teams trusted in 2019 no longer describe the market they are negotiating in.
